For example, National Comprehensive Cancer Network (NCCN) guidelines (version 2.2018) recommend KRAS, NRAS and BRAF mutation detection in metastatic colorectal carcinoma(CRC) for the well-established role in predicting therapeutic response [1]. Here, KRAS is linked to colorectal carcinoma.